Brainsway (BWAY) Projected to Post Earnings on Tuesday

Brainsway (NASDAQ:BWAY) is projected to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $13.0350 million for the quarter. Brainsway has set its FY 2025 guidance at EPS.Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:30 AM ET.

Brainsway (NASDAQ:BWAY) last announced its earnings results on Wednesday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.03. Brainsway had a net margin of 11.60% and a return on equity of 8.97%. The business had revenue of $12.63 million during the quarter, compared to analyst estimates of $12.34 million. On average, analysts expect Brainsway to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Brainsway Stock Down 2.4%

Shares of Brainsway stock traded down $0.42 during trading on Tuesday, reaching $16.96. The company’s stock had a trading volume of 8,647 shares, compared to its average volume of 57,205. The firm’s 50-day moving average is $15.77 and its two-hundred day moving average is $12.87. Brainsway has a 52-week low of $7.84 and a 52-week high of $17.92. The company has a market cap of $322.32 million, a price-to-earnings ratio of 65.66 and a beta of 1.22.

Institutional Investors Weigh In On Brainsway

A hedge fund recently bought a new stake in Brainsway stock. Raymond James Financial Inc. bought a new stake in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 6,488 shares of the company’s stock, valued at approximately $85,000. 30.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on BWAY. Wall Street Zen raised shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Sunday, August 17th. HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Brainsway in a research note on Monday, August 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Brainsway in a research note on Tuesday, October 14th. Finally, Northland Securities raised their target price on shares of Brainsway from $15.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday, August 14th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Brainsway currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.